Flare phenomenon in positron emission tomography in a case of breast cancer—a pitfall of positron emission tomography imaging interpretation


      We present an unusual case of breast cancer with increased FDG uptake 4 months after chemotherapy. A PET-CT scan displayed results that mimicked multiple lymph node metastases in the right axilla, the mediastinum, and the bilateral pulmonary hilar regions. However, the increased FDG uptake disappeared 17 months later without any additional medical treatment, suggesting the occurrence of flare phenomenon.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jansson T
        • Westlin JE
        • Ahlstrom H
        • Lilja A
        • Langstrom B
        • Bergh J
        Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?.
        J Clin Oncol. 1995; 13: 1470-1477
        • Krak NC
        • van der Hoeven JJ
        • Hoekstra OS
        • Twisk JW
        • van der Wall E
        • Lammertsma AA
        Measuring [18F] FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
        Eur J Nucl Med Mol Imaging. 2003; 30: 674-681
        • Zangheri B
        • Messa C
        • Picchio M
        • Gianolli L
        • Landoni C
        • Fazio F
        PET/CT and breast cancer.
        Eur J Nucl Med Mol Imaging. 2004; 31: S135-S142
        • Biersack HJ
        • Bender H
        • Palmedo H
        FDG-PET in monitoring therapy of breast cancer.
        Eur J Nucl Med Mol Imaging. 2004; 31: S112-S117
        • Hicks RJ
        The role of PET in monitoring therapy.
        Cancer Imaging. 2005; 5: 51-57
        • Smith IC
        • Welch AE
        • Hutcheon AW
        • Miller ID
        • Payne S
        • Chilcott F
        • et al.
        Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
        J Clin Oncol. 2000; 18: 1676-1688
        • Mankoff DA
        • Dunnwald LK
        • Gralow JR
        • Ellis GK
        • Schubert EK
        • Tseng J
        • et al.
        Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
        J Nucl Med. 2003; 44: 1806-1814
        • Dehdashti F
        • Flanagan FL
        • Mortimer JE
        • Katzenellenbogen JA
        • Welch MJ
        • Siegel BA
        Positron emission tomography assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy.
        Eur J Nul Med. 1999; 26: 51-56
        • Young H
        • Baum R
        • Cremerius U
        • Herholz K
        • Hoekstra O
        • Lammertsma AA
        • et al.
        Measurement of clinical and subclinical tumor response using 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group.
        Eur J Cancer. 1999; 35: 1773-1782
        • Basu S
        • Alavi A
        Defining co-related parameters between ‘metabolic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and establishing guidelines for assessing response to treatment in cancer.
        Eur J Nucl Med Mol Imaging. 2007; 34: 441-443